Medical Devices

As childhood nearsightedness soars, a new contact lens offers hope by not just correcting vision but actively slowing its progression in key global markets.

Zymeworks lands $250M from Royalty Pharma in a non-dilutive deal, validating its cancer drug Ziihera and highlighting a new era of biotech financing.

With positive Phase 3 data for its first-in-class Stargardt disease drug and a massive new financing round, Belite Bio pivots toward commercialization.

An 8-month-old infant weighing just 5.5 kg receives a new liver from his father in a daring surgery, marking a milestone for pediatric care in India.

The FDA has greenlit Ascendis Pharma's once-weekly YUVIWEL for achondroplasia, a major step for patients that also carries significant business implications.

Celebrating its first anniversary, this derm-founded brand is swapping viral trends for sustainable growth, community building, and a new scholarship.

As UFP Technologies preps for a key investor conference, its stellar growth, strategic acquisitions, and vital role in the MedTech supply chain are in focus.

A new partnership brings a high-speed digital pathology scanner to the U.S. for the first time, promising to revolutionize diagnostic speed and accuracy.

With U.S. cancer centers tripling adoption of its targeted drug delivery device, RenovoRx signals a potential shift in treating solid tumors.

With new funding and veteran US leadership, UK-based OSSTEC is preparing to launch its innovative ASCENT partial knee system in a competitive market.

On Rare Disease Day, Polaryx Therapeutics advances a novel oral drug in a pivotal trial for four devastating pediatric disorders, offering a new strategy.

A new emergency epilepsy medication for children is now available, offering a faster, easier-to-use option for caregivers to stop prolonged seizures.

The organ transplant innovator's massive Q4 profit came from a tax rule, but it signals a major turning point and confidence in long-term profitability.

Treace Medical reports a Q4 revenue dip despite surgeon growth, revealing a strategic shift to lower-priced kits and a challenging 2026 outlook.

A new oral therapy, mavorixafor, receives a key recommendation in Europe, offering a beacon of hope for patients with a debilitating ultra-rare immune disorder.

After a 25-year era of global growth, Lansinoh appoints Julie Talbot to redefine parental support and scale a new, empathetic vision worldwide.

Medit's new initiative links scanner purchases to children's dental care, sparking a conversation on corporate responsibility in the dental tech industry.

Tectonic Therapeutic reports key clinical progress in two distinct rare diseases, backed by a strong cash position and new leadership for its next phase.

Neurizon Therapeutics has started dosing its promising ALS drug, NUZ-001, in the groundbreaking HEALEY Platform Trial, a pivotal step for patients.

The 3M spin-off navigates a transformative year, posting strong organic growth driven by MedSurg and Dental, despite a reported sales dip from divestitures.